查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1139263

護理點 (POC) 數據管理軟件市場 - 增長、趨勢、COVID-19 影響和預測（2022-2027 年）

Point-of-Care Data Management Software Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，床旁 (POC) 數據管理軟件市場預計將以 12.3% 的複合年增長率增長。

護理點技術使醫院和診所能夠將更多時間用於技術，以加快患者通過護理的流程、減少等待時間並簡化醫生和護士的日常工作流程。並且可以投資成本。

主要亮點

  • 隨著醫療保健領域不斷變化的價值觀和技術發展，對床旁 (POC) 檢測的需求不斷增長。有幾個因素推動了對 POCT 的需求。例子包括傳染病的增加、心髒病和糖尿病等生活方式疾病的增加、患者對家用 POC 設備的需求增加，以及創造更快、更易於使用的設備的技術進步。
  • 在全球範圍內，估計有 5.11 億成年人患有糖尿病。到 2040 年，這個數字預計將上升到 5.7 億以上。隨著全球糖尿病患病率持續上升，還需要努力提高認識。預計亞太地區將有 37% 的糖尿病患者居住。此外，根據國際糖尿病聯合會的數據，到 2021 年，全球將有 5.37 億糖尿病患者。從 2021 年到 2045 年，全球糖尿病護理支出預計將從 9.66 億美元增長到 10.53 億美元。根據美國疾病控制和預防中心 (CDC) 最近的一份報告，超過 50% 被診斷為 COVID-19 的糖尿病患者住院。
  • 通過即時檢測 (POCT) 快速診斷臨床症狀可以改善患者預後。 POCT 發展背後的一個關鍵概念是通過使測試更接近患者並將結果快速方便地提供給醫療保健提供者來加速診斷和治療。今天的 POCT 設備已經發生了變化，但獲取記錄合規性所需的數據仍然很耗時。強大的 POCT 管理系統和連接解決方案減少了手動輸入結果所需的時間，消除了手動輸入中固有的錯誤，並促進了實時訪問結果，以確保醫療保健專業人員及時做出決策。讓您做出決定。
  • 此外，隨著醫療保健數據分析越來越普遍地用於支持以患者為中心的護理和人口健康管理，以電子方式整合 POCT 結果以跟蹤結果和納入關鍵績效指標變得至關重要。從 2015 年到 2019 年，美國的電子健康記錄 (EHR) 支出將以 5.4% 的複合年增長率增長，到 2019 年將達到 145 億美元。此外，根據日本看護協會的一項調查，從 2019 年 9 月到 2019 年 10 月，日本約有 63% 的醫院已經引入了 EMR 系統。自 2000 年代初以來，政府一直在推廣該系統的使用。
  • COVID-19 的爆發給世界各地的醫療保健系統帶來了巨大壓力，因為他們正努力應對大量需要挽救生命的治療的病人。一些國家正在尋找和準備關鍵的醫療設備，例如外科口罩、面罩、救生呼吸機或為患者提供的物理空間和床位。這些看似基本的必需品已成為高科技醫療設備領域的優先事項。

主要市場趨勢

醫院/重症監護中心有望佔據很大的市場份額

  • 醫院越來越多地使用 POCT（即時檢測）和電子病歷系統，實時電子結果報告的重要性與日俱增。 POCT 數據管理系統不斷發展以響應不斷變化的市場需求以支持此類模型。從校園到校園，或從州/省到省以及跨醫院，基於網絡的連接數據管理平台釋放了即時檢測項目管理的關鍵效率。
  • POC（Point of Care）技術最重要的方面是它的床邊存在。 POC 技術促進並改善了患者與護士、醫生和外科醫生之間的互動，從而帶來更好的醫療保健結果。床邊血糖測試是 POC 市場中最普遍和最大的量。這些是第一批開發的設備，涉及數百台設備和數千名操作員。
  • 此外，每個房間和治療區域的壁掛式 POC 終端和帶輪工作站都有可能為任何醫院節省大量時間和金錢。各種研究得出的結論是，護士將 25-50% 的輪班時間用於在物理圖表上以傳統方式（鉛筆和紙）完成文檔。換句話說，護士經常參與準確檢索、創建、修改和存儲關鍵患者數據。
  • 此外，重症監護病房 (ICU)/重症監護病房的臨床醫生經常在密閉空間內收治重症患者，此時需要快速做出決定。因此，POCT 越來越多地被用作重症監護的常規組成部分，尤其是用於血氣分析。血氣分析儀（BGA）的主要目的是準確測量血氣濃度（pH、pO2、pCO2等），但現代分析儀目前缺乏血紅蛋白和電解質濃度（鈉、鉀、氯）、離子鈣等.) 可以在相同的血液樣本中進行測量。
  • 西班牙一家醫院正在與 NTT DATAzGroup 合作開發 SmartICU，在那裡醫生和技術人員與 NTT DATA 數據科學家合作，以實現更好的臨床結果。在與醫院合作開發 SmartICU 解決方案的為期一年的旅程開始時，該團隊將數據管理和報告確定為主要障礙。
  • 鑑於護士的非結構化手動每小時讀數，關鍵單位的數據源遠遠超出高級儀器讀數。每個團隊都花費了一定的時間來發現和整合數據、設計和定制報告儀表板。有了這個基礎，醫院和 NTT DATA 團隊決定專注於最具附加值的分析場景，並在此基礎上進行分層。

預計北美將佔據很大的市場份額

  • 數十年來，北美地區一直使用即時檢測 (POCT) 來診斷和監測急性和慢性疾病。用於診斷艾滋病、肺結核和瘧疾等傳染病的快速檢測的可用性，主要是由於醫生和患者能夠通過智能手機將結果可視化並做出更好的臨床決策。未來幾年市場可能會發生變化。此外，即時診斷市場受到診斷行業最新創新的推動，這些創新為快速臨床決策提供快速診斷，以支持治療方案。
  • 根據美國疾病控制和預防中心的數據，COPD 和哮喘等慢性下呼吸道疾病是美國第四大死因。每年有超過 160,000 人死亡。在美國，五分之一的 COPD 患者將在 30 天內重新入院。
  • 政府採用 POC 是當務之急。 POC 測試減少了對醫院資源的壓力，還可以減少 ER 等待時間和就診。生產中的大多數 POC 測試旨在檢測傳染病。例如，由美國國家生物醫學成像研究所建立的 POC 技術研究網絡正在加速 POC 診斷和檢測產品的開發。諸如臨床實驗室改進法案 (CLIA) 指南等有利法規促進了 POC 測試優於其他形式。
  • 目前，美國 POC 檢測包括化學/電解質、妊娠、血紅蛋白、心臟生物標誌物、血液學、糞便潛血、濫用藥物、肝功能、血氣和有限感染。由於現有的心臟生物標誌物 POC 測試存在缺陷，MEDITECH 的 Expanse Point of Care 軟件、用於護士和治療師與患者互動並提供最佳和最有效護理的最新網絡移動技術已被引入 King's Daughters 醫療中心消滅傳染病的目的。根據地理位置和潛在的傳染病，POC 資源可以針對流行病、複雜的緊急情況或災難進行定制。
  • 隨著醫療界努力尋找准確、及時的虛擬策略來改善患者護理，尤其是在 COVID-19 大流行期間，Evoke360 正在幫助提高護理質量和患者治療效果。同時影響質量和風險調整後的分數，提高利潤率並為供應商組織提供競爭優勢。 2020 年 6 月，DataLink Software (DataLink) 指出了 Evoke360 及其提供者關係管理 (PRM) 模塊的主要優勢，使提供者能夠從按服務收費轉向基於價值的護理。 Evoke360 充當護理點解決方案，聚合來自不同來源的數據以加速搶先式患者護理，彌合護理差距以超越診斷。

競爭格局

醫療點 (POC) 數據管理軟件市場是一個競爭激烈的市場，有多家公司進入該市場。市場適度分散，主要參與者似乎正在採取產品創新、併購等策略來擴大市場範圍並保持競爭力。市場上的主要參與者包括 Siemens Healthineers AG、Abbott Point of Care Inc.、Danaher Corporation 等。

  • 2022 年 1 月，格力泰與羅氏就胰島素管理展開合作。數字健康合作夥伴關係將羅氏在醫療設備和 IT 解決方案方面的專業知識與 Glitech 的 FDA 批准的胰島素劑量決策支持軟件 GluCommander 相結合，以解決住院患者在醫院床邊血糖控制方面的挑戰。旨在使護理點臨床醫生能夠收集並立即對血糖控制數據採取行動，以改善患者安全和護理。
  • 2022 年 2 月，數字健康公司 Butterfly Networks 與領先的基於雲的醫學圖像管理套件的製造商 Intelerad 公司 Umbra Health 宣佈建立合作夥伴關係，以加速和簡化圖像數據互操作性。該合作夥伴關係增強了 Butterfly Blueprint 企業平台的可擴展性，增加了醫院和醫療保健系統之間有價值的超聲信息的訪問和共享。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法

第 3 章執行摘要

第 4 章市場動態

  • 市場概覽
  • 市場驅動力
    • 靈活連接和軟件接口解決方案的創新
    • 增加醫療基礎設施預算
    • 政府為推廣 POC 測試所做的努力
  • 市場挑戰
    • 高昂的引入成本和運營挑戰
  • 市場機會
    • 快速檢測和分散式醫療保健
  • 波特五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 當前監管狀態（臨床實驗室改進法案 CLIA 指南和連接標準 (POCT1-A2)
  • 床旁檢測的新應用（敗血症生物標誌物、內分泌檢測、中風標誌物等）。

第 5 章 COVID-19 對市場的影響

第 6 章市場細分

  • 按最終用戶
    • 醫院/重症監護中心
    • 診斷中心
    • 診所/門診
  • 按應用
    • 傳染病防治設備
    • 血糖監測
    • 血液凝固測量儀
    • 尿液分析
    • 循環代謝監測
    • 癌症標記
    • 血液學
    • 其他 POC 應用
  • 地區信息
    • 北美
      • 美國
      • 加拿大
    • 歐洲
      • 德國
      • 英國
      • 意大利
      • 法國
      • 其他歐洲地區
    • 亞太地區
      • 印度
      • 日本
      • 中國
      • 新加坡
      • 其他亞太地區
    • 拉丁美洲
    • 中東和非洲

第 7 章競爭格局

  • 公司簡介
    • Siemens Healthineers AG+（Conworx）
    • Abbott Point of Care Inc.+（Alere）
    • Danaher Company（HemoCue and Radiometer Medical ApS）
    • Roche Diagnostics Corporation
    • TELCOR Inc.
    • Orchard Software Corporation
    • Randox Laboratories Ltd
    • Thermo Fisher Scientific Inc.

第8章 投資分析

第9章 市場的將來性

簡介目錄
Product Code: 71564

The POC data management software market is expected to register a CAGR of 12.3% over the forecast period. Point-of-care technologies enable hospitals and clinics to invest more time and money in technologies that help accelerate the patient flow through practice and streamline doctors' and nurses' daily workflow by reducing waiting times.

Key Highlights

  • The demand for point-of-care testing is growing in response to the value shift in healthcare and technological developments. Several factors are driving the need for POCT. Some of them include an increase in infectious diseases, a rise in lifestyle-related diseases, such as cardiac diseases and diabetes, a growing patient desire to use home-based POC devices, and technological advancements creating faster and easier-to-use devices.
  • Around the globe, an estimated 511 million adults have diabetes. By 2040, this number is expected to rise to over 5,70 million. As diabetes worldwide continues to increase, so must the effort to raise awareness. 37% of all diabetic adults are expected to live in the Asia-Pacific region. Additionally, according to the International Diabetes Federation, the number of diabetic patients worldwide in 2021 was 537 million. Between 2021 - 2045, the global expenditures for diabetes treatment are anticipated to grow from USD 966 million to USD 1,053 million. According to a recent report by the Centers for Disease Control and Prevention (CDC), more than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized.
  • Rapid diagnosis of clinical conditions through point-of-care testing (POCT) can improve patient outcomes. The primary concept behind POCT growth is that bringing testing closer to the patient and results quickly and conveniently to the provider can speed up the diagnosis and treatment. Today's POCT devices are changing, but capturing the data required to document compliance is still time-consuming. A robust POCT management system and connectivity solution reduces the time spent manually typing in results, eliminates errors inherent to manually entered results, and facilitates real-time access to results so that providers can make timely decisions.
  • Additionally, as healthcare data analytics are more commonly used to support patient-centered care and population health management, it is essential to have POCT results electronically integrated to include results tracking metrics and key performance indicators. Electronic medical records (EHR) expenditures in the United States grew at an annual average of 5.4% from 2015 to 2019, totaling USD 14.5 billion in 2019. Additionally, according to the Japanese Nursing Association survey, from September to October 2019, around 63% of the hospitals in Japan implemented the system of EMR. The government in the country has been promoting the system's use since the beginning of the 2000s.
  • The COVID-19 outbreak placed a significant burden on healthcare systems worldwide that are straining to handle the volume of ill patients requiring life-saving treatment. Several countries have witnessed or are preparing for shortages of critical medical equipment such as surgical masks, face shields, life-saving ventilators, or even the physical space and beds for patients. These seemingly fundamental necessities become the priority in a world of increasingly high-tech healthcare equipment.

Key Market Trends

Hospitals/Critical Care Units Segment is Expected to Hold a Significant market Share

  • The point-of-care testing (POCT) and electronic medical records system usage are rising in hospitals, where the importance of real-time electronic reporting of results is increasing. POCT data management systems are evolving to meet the marketplace's changing needs in supporting such a model. Across the hospitals, either from campus to campus or from one state/province to another, the web-based connectivity data management platform unlocks primary efficiency in point-of-care testing program management.
  • The most critical aspect of POC (point-of-care) technology is its presence at the bedside. POC technologies facilitate and improve interactions between patients and their nurses, doctors, and surgeons, leading to better healthcare outcomes. Bedside glucose testing is the most widespread and occupies the most massive volume in the POC market. These were the first devices developed and involved hundreds of devices and thousands of operators.
  • Further, a wall-mounted POC terminal in every room/treatment area or workstation on wheels has the potential to create significant time and cost savings in any hospital. Various studies concluded that nurses spend 25-50% of their shifts on documentation done in the traditional manner, which is on a physical chart with a pencil and paper. This means that nurses are regularly involved in accurate retrieval, production, modification, and critical patient data storage.
  • Further, clinicians in intensive care units (ICU)/critical care units often work with critically ill patients in limited space and must make quick decisions at that point of care. Thus, critical care units have increasingly used POCT as a routine element of patient management, notably for blood gas analysis. The primary objective of the blood gas analyzer (BGA) is to deliver accurate measures of the blood gas levels (such as pH, pO2, and pCO2); however, modern analyzers can currently measure additional parameters in the same blood sample, such as the hemoglobin or electrolyte concentrations (includes sodium, potassium, chloride, and ionized calcium).
  • The development of SmartICU at a hospital in Spain, in partnership with NTT DATA (an NTT DATAzGroup), is teaming its doctors and technologists with NTT DATA's data scientists to get better clinical results. At the outset of a one-year journey of developing the SmartICU solution with the hospital, the team identified data management and reporting as the primary obstacle.
  • Data sources at the critical units go far beyond high-level device readings when one considers them unstructured, such as the nurse's hourly measurements manually. The teams spent a certain amount of time on data discovery, integration, reporting dashboard designing, and customizing. With this foundation, the hospital and NTT DATA teams have focused on the most value-adding analytic scenarios to layer on top.

North America is Expected to Hold a Significant Market Share

  • Point-of-care testing (POCT) has been used in the North American region for several decades to diagnose and monitor acute and chronic medical conditions. The growing availability of rapid tests for diagnosing infectious diseases, such as HIV, TB, or malaria, that primarily enable physicians and patients to visualize the results from a smartphone and make appropriate clinical decisions may transform the market over the next few years. The point-of-care diagnostics market is also driven by the latest innovations in the diagnostics industry to provide an expedited diagnosis for quick clinical decision-making to support treatment regimens.
  • According to the Centers for Disease Control and Prevention, chronic lower respiratory diseases, including COPD and asthma, are the fourth-leading causes of mortality in the United States. They are responsible for more than 160,000 deaths a year. It is expected that 1 in 5 COPD patients will be readmitted within 30 days in the United States.
  • There is a preference for POC adoption by governments. POC testing reduces the strain on hospital resources, as well as ER wait times and visits. The majority of POC tests produced are designed for detecting infectious diseases. For instance, the Point of Care Technologies Research Network established by the United States National Institute of Biomedical Imaging and Bioengineering accelerates POC diagnostics or testing product development. Favorable regulations, such as the Clinical Laboratory Improvement Amendments (CLIA) guidelines, promote POC testing over other forms.
  • Presently, US POC testing caches comprise chemistry/electrolytes, pregnancy, hemoglobin, cardiac biomarkers, hematology, fecal occult blood, drugs of abuse, liver function, blood gases, and limited infectious diseases. Owing to the deficiencies with existing POC tests for cardiac biomarkers, MEDITECH's Expanse Point of Care software, the company's latest web-based mobile technology for nurses and therapists to provide the best and most efficient patient-facing care, has been implemented at King's Daughters Medical Center, aiming to eliminate infectious diseases. Depending on geographic location and potential infectious diseases, POC resources can be customized for pandemics, complex emergencies, or disasters.
  • As the healthcare community scrambles for accurate, timely, and virtual strategies to improve patient care, especially amid the COVID -19 pandemic, Evoke360 not only enhances the quality of care and patient outcomes but also impacts quality and risk adjustment scores that increase profit margins and give provider organizations a competitive edge. In June 2020, DataLink Software (DataLink) pointed to the key advantages of Evoke360 and its Provider Relations Management (PRM) module, enabling providers to transition from fee-for-service to value-based care. Evoke360 serves as a point-of-care solution, aggregating data from disparate sources to accelerate preemptive patient care, closing gaps in care to treat more than the diagnosis results.

Competitive Landscape

The Point-of-Care Data Management Software Market is highly competitive, owing to the presence of multiple players in the market. The market appears to be moderately fragmented, with the key players adopting strategies such as product innovation, mergers, and acquisitions, to expand their reach and stay competitive in the market. Some of the market's major players are Siemens Healthineers AG, Abbott Point of Care Inc., and Danaher Corporation, among others.

  • In January 2022, Glytec and Roche struck a partnership on insulin management. This digital health collaboration combines Roche's expertise in medical devices and IT solutions with Glytec's FDA-cleared insulin dosing decision support software, Glucommander, to address the challenges with inpatient blood sugar management at the hospital bedside, designed to improve patient safety and care by empowering point-of-care clinicians to collect and take immediate action on glycaemic management data.
  • In February 2022, Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ultrasound, and Ambra Health, an Intelerad Company and maker of a leading cloud-based medical image management suite, announced a partnership to accelerate and simplify interoperability for bedside imaging data. This partnership strengthens Butterfly Blueprint's enterprise platform's scalability and will enhance access and shareability of valuable ultrasound information across hospitals and health systems.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Innovation in Flexible Connectivity and Software Interface Solutions
    • 4.2.2 Rise in Healthcare Infrastructure Budgets
    • 4.2.3 Government Initiatives for Promoting the Deployment of POC Testing
  • 4.3 Market Challenges
    • 4.3.1 High Deployment Costs and Operational Challenges
  • 4.4 Market Opportunities
    • 4.4.1 Rapid Testing and Decentralized Healthcare
  • 4.5 Porters Five Force Analysis
    • 4.5.1 Bargaining Power of Suppliers
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Threat of New Entrants
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Intensity of Competitive Rivalry
  • 4.6 Current Regulatory Landscape (Guidelines of Clinical Laboratory Improvement Amendments CLIA) and Connectivity Standards (POCT1-A2))
  • 4.7 Emerging Applications in Point-of-Care Testing (Sepsis Biomarkers, Endocrine Testing, Stroke Markers, etc.)

5 IMPACT OF COVID-19 ON THE MARKET

6 MARKET SEGMENTATION

  • 6.1 By End User
    • 6.1.1 Hospitals/Critical Care Units
    • 6.1.2 Diagnostic Centers
    • 6.1.3 Clinics/Outpatient
  • 6.2 By Application
    • 6.2.1 Infectious Disease Devices
    • 6.2.2 Glucose Monitoring
    • 6.2.3 Coagulation Monitoring
    • 6.2.4 Urinalysis
    • 6.2.5 Cardiometabolic Monitoring
    • 6.2.6 Cancer Markers
    • 6.2.7 Hematology
    • 6.2.8 Other POC Applications
  • 6.3 By Geography
    • 6.3.1 North America
      • 6.3.1.1 United States
      • 6.3.1.2 Canada
    • 6.3.2 Europe
      • 6.3.2.1 Germany
      • 6.3.2.2 United Kingdom
      • 6.3.2.3 Italy
      • 6.3.2.4 France
      • 6.3.2.5 Rest of Europe
    • 6.3.3 Asia-Pacific
      • 6.3.3.1 India
      • 6.3.3.2 Japan
      • 6.3.3.3 China
      • 6.3.3.4 Singapore
      • 6.3.3.5 Rest of Asia-Pacific
    • 6.3.4 Latin America
    • 6.3.5 Middle East & Africa

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Siemens Healthineers AG + (Conworx)
    • 7.1.2 Abbott Point of Care Inc. + (Alere)
    • 7.1.3 Danaher Company (HemoCue and Radiometer Medical ApS)
    • 7.1.4 Roche Diagnostics Corporation
    • 7.1.5 TELCOR Inc.
    • 7.1.6 Orchard Software Corporation
    • 7.1.7 Randox Laboratories Ltd
    • 7.1.8 Thermo Fisher Scientific Inc.

8 INVESTMENT ANALYSIS

9 FUTURE OF THE MARKET